Welcome to our dedicated page for OKYO PHARMA news (Ticker: OKYO), a resource for investors and traders seeking the latest updates and insights on OKYO PHARMA stock.
OKYO Pharma Ltd (OKYO) is a clinical-stage biopharmaceutical company pioneering novel therapies for ocular inflammatory conditions and neuropathic pain. This page serves as the definitive source for official company announcements, including clinical trial updates, regulatory developments, and strategic partnerships.
Investors and researchers will find timely updates on OKYO's lead candidate OK-101, a patented chemerin analog targeting dry eye disease and corneal neuropathic pain. All content is sourced directly from company filings and press releases to ensure accuracy.
The news archive includes updates on: Phase 2 clinical trial progress, intellectual property milestones, research collaborations, and regulatory pathway developments. Content is organized chronologically for tracking therapeutic advancement timelines.
Bookmark this page for streamlined access to OKYO's latest scientific and corporate developments. Check regularly for updates on ocular therapeutic innovations with potential to address unmet medical needs in global markets.
OKYO Pharma (NASDAQ: OKYO) has secured $1.9 million in non-dilutive funding to accelerate the development of urcosimod, its lead drug candidate for treating Neuropathic Corneal Pain (NCP). The funding will support ongoing R&D programs and advance clinical milestones without impacting existing shareholder equity.
NCP is a severely debilitating ocular condition characterized by chronic nerve-related pain that currently has no FDA-approved treatments. The company will use the funds to advance clinical development, expand R&D efforts, and progress urcosimod's regulatory pathway, demonstrating its commitment to fiscal responsibility while developing innovative therapies.
OKYO Pharma (NASDAQ: OKYO) has announced positive Phase 2 clinical trial results for urcosimod in treating neuropathic corneal pain (NCP). The trial demonstrated that 75% of per-protocol patients receiving 0.05% urcosimod achieved over 80% reduction in pain after 12 weeks of treatment.
Key findings include a statistically significant reduction in mean pain scores (p-value = 0.025) for the 0.05% urcosimod group, with efficacy observed as early as Week 4. The drug showed particularly strong results in patients with moderate to severe NCP pain scores. Importantly, no serious adverse events were reported among the 18 trial participants.
The company plans to meet with the FDA to discuss next steps for urcosimod, which has already received Fast Track designation. OKYO is also planning to arrange an Expanded Access program for the drug, pending FDA approval.
OKYO Pharma (NASDAQ: OKYO) announced that CEO Gary S. Jacob will present at the 4th Annual GPCRs-Targeted Drug Discovery Summit in Boston on May 22, 2025. The presentation will focus on the development of urcosimod, the company's lead clinical drug candidate for treating neuropathic corneal pain (NCP).
NCP is a debilitating condition affecting tens of thousands worldwide, characterized by chronic, severe eye discomfort. Currently, there is no FDA-approved therapy for this condition. The presentation will take place at the Revere Hotel Boston Common and will detail urcosimod's targeting of CMKLR1 (ChemR23) for NCP treatment.
OKYO Pharma announces plans to accelerate the development of urcosimod for treating Neuropathic Corneal Pain (NCP). The company is closing its Phase 2 trial early after 17 patients completed the study at Tufts Medical Center in Boston.
The trial, initiated in October 2024, was designed as a double-masked, randomized, 12-week placebo-controlled study. The decision to end early stems from OKYO's desire to analyze the current data and expand to a multicenter trial. Several patients who completed the trial have requested continued compassionate use of urcosimod.
The company expects data analysis to take approximately 6 weeks and plans to meet with the FDA to discuss accelerated development plans. Urcosimod has already shown favorable safety and placebo-like tolerability in a previous 240-patient Phase 2 trial. NCP currently has no FDA-approved therapy, making this development significant for patients who have had limited success with other treatments.
OKYO Pharma (NASDAQ: OKYO) has announced significant stability data for its drug candidate urcosimod, currently in Phase 2b clinical trials for Neuropathic Corneal Pain (NCP). The drug has demonstrated remarkable stability in single-use ampoules over a 2½-year period under refrigerated conditions, with stability rates of 94.8% for 0.05% concentration and 97.4% for 0.1% concentration.
The stability testing is a important requirement for FDA approval, addressing shelf-life concerns for the drug. Additionally, room temperature stability testing has shown promising early results, with 3-month stability rates at or above 100%. The company notes that single-use ampoules are increasingly preferred for ophthalmic drugs over plastic bottles, offering better sterility control for long-term daily administration.
Urcosimod is being evaluated in a randomized, placebo-controlled, double-masked trial involving 48 patients for NCP, a severe ocular condition currently lacking FDA-approved treatments. The drug has also shown potential in treating inflammatory dry eye disease (DED), a multi-billion-dollar market opportunity.
OKYO Pharma (NASDAQ: OKYO) has filed an application for Fast Track designation with the FDA for its drug urcosimod (formerly OK-101) to treat neuropathic corneal pain. This condition, affecting tens of thousands globally, is characterized by chronic, severe eye discomfort with no current FDA-approved treatment.
The company is developing urcosimod for both neuropathic corneal pain and inflammatory dry eye disease, the latter representing a multi-billion-dollar market opportunity. Fast Track designation is designed to expedite the development and review process for drugs treating serious conditions that lack FDA-approved treatments.
OKYO Pharma (NASDAQ: OKYO) announced that its lead drug candidate OK-101 has been officially assigned the United States Adopted Name (USAN) 'urcosimod'. The drug is currently in Phase 2 clinical trials for neuropathic corneal pain (NCP), a condition without FDA-approved treatments, and has shown promising results in Phase 2 trials for inflammatory dry eye disease (DED).
Urcosimod is a lipid-conjugated small molecule designed to target ocular G-protein coupled receptors (GPCRs), combining anti-inflammatory and pain-modulating properties. The ongoing Phase 2 trial for NCP, initiated in October 2024, is expected to release top-line results in Q4 2025. The suffix '-mod' in the name reflects its role as a modulator of inflammatory and neuropathic pathways.